IGC Announces Financial Results for Fiscal Year Ended March 31, 2016

Expands Phytocannabinoid IP Portfolio

Bethesda, Maryland, UNITED STATES

BETHESDA, Md., July 18, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces financial results for the fiscal year ended March 31, 2016. 

Total revenue was approximately $6.37 million for the year ended March 31, 2016, as compared to approximately $7.68 million for the year ended March 31, 2015, a decrease of about 17.4%. In both fiscal years our main revenue driver was electronic component trading with revenue performance based on volume and product diversity.

Selling, general and administrative expenses were approximately $2.7 million for fiscal 2016 as compared to approximately $4.14 million for fiscal 2015, an improvement of 34.8%. The overall SG&A for fiscal 2016 consists primarily of (i) non-cash charges associated with ESOP and other share issuances; (ii) one-time expenses associated with the acquisition of Ultima; and (iii) R&D expenses for the development of phytocannabinoid-based therapies. Adjusted for these events, the SG&A for fiscal 2016 reflects a steep cut in expenses associated with a further realignment of resources with the current business plan

Loss from operations was approximately $2.9 million in fiscal year 2016, as compared to approximately $4.34 million in fiscal year 2015. The improvement in operating loss year over year is attributed to lower SG&A.

In fiscal year 2016, our investment in others was approximately $5.17 million and at March 31, 2015 it was about $0.031 million. The increase in investment stems from the acquisition of land in Nagpur India that was part of the settlement with Sricon. This is a reclassification from Investment in affiliates.

At the end of fiscal year 2016, the Company has approximately $1.49 million in cash and cash equivalents.  In fiscal 2016, the non-GAAP total cash burn after adjusting for non-cash items that include ESOPs, interest payments paid in stock, foreign exchange losses, one time acquisition related expenses, and other miscellaneous non-cash items, was approximately $0.856 million.  This is attributable largely to public company related expenses as our operating business was marginally profitable.

Our strategy in fiscal 2016 and fiscal 2017 is: (i) to develop an addressable market product portfolio of phytocannabinoid-based therapies for end of care and compassionate use; (ii) wind down the low margin electronic parts supply business; and (iii) re-focus on infrastructure and real estate development. 

Financial Tables to Follow

All amounts in USD except share data As of 
  31-March - 16  31-March - 15 
  (audited)  (audited) 
Current assets:      
Cash and cash equivalents $1,490,693  $824,492 
Accounts receivable, net of allowances  962,658   993,296 
Inventories  162,091   709,649 
Prepaid expenses and other current assets  1,226,507   1,950,295 
Total current assets $3,841,949  $4,477,732 
Goodwill  1,180,951   982,782 
Intangible Assets  113,321   306,131 
Property, plant and equipment, net  7,074,437   7,784,447 
Investments in affiliates  609,148   5,997,058 
Investments-others  5,175,392   30,477 
Deferred Income taxes  356,684   318,548 
Other non-current assets  507,300   434,284 
Total long-term assets $15,017,233  $15,853,727 
Total assets $18,859,182  $20,331,459 
Current liabilities:        
Short -term borrowings  27,762   1,280,356 
Trade payables  330,631   174,584 
Accrued expenses  300,111   422,252 
Loans - others  189,680   73,707 
Notes payable  1,800,000   - 
Other current liabilities  550,877   496,985 
Total current liabilities $3,199,061  $2,447,884 
Long -term borrowings  801,467   323,904 
Notes payable  -   1,800,000 
Other non-current liabilities  910,583   1,009,889 
  $1,712,050  $3,133,793 
Total liabilities $4,911,111  $5,581,677 
Stockholders' equity:        
Common stock — $.0001 par value; 150,000,000 shares authorized; 14,766,333 issued and outstanding as of March 31, 2015 and 23,265,531 issued and outstanding as of March 31, 2016. $2,327  $1,477 
Additional paid-in capital  65,885,243   63,479,918 
Accumulated other comprehensive income  (2,269,357)  (1,913,585)
Retained earnings (Deficit)  (50,142,199)  (47,333,955)
Total equity attributable to Parent $13,476,014  $14,233,855 
 Non-controlling interest $472,057  $515,927 
Total stockholders' equity $13,948,071  $14,749,782 
Total liabilities and stockholders' equity $18,859,182  $20,331,459 
These financial statements should be read in connection with the accompanying notes on Form 10-K for fiscal 2016 filed with the SEC on July 14, 2016. 

  All amounts in USD except share data 
  Year ended March 31, 
 2016  2015 
Revenues $6,366,550  $7,680,257 
Cost of revenues (excluding depreciation)  (5,523,256)  (7,100,568)
Selling, general and administrative expenses  (2,702,753)  (4,140,434)
Depreciation  (728,741)  (781,546)
Loss on investments / associates /joint ventures  (317,510)  - 
Operating income (loss) $(2,905,710) $(4,342,291)
Interest expense  (213,928)  (286,332)
Interest income  2,085   6,799 
Other income, net  284,186   (56,367)
Income before income taxes and minority interest attributable to non-controlling interest $(2,833,367) $(4,678,191)
Income taxes benefit/ (expense)  (579)  (5,157)
Net income/(loss) $(2,833,946) $(4,683,348)
Non-controlling interests in earnings of subsidiaries  (25,702)  (69,165)
Net income / (loss) attributable to common stockholders $(2,808,244) $(4,614,183)
Earnings/(loss) per share attributable to common stockholders:        
Basic $(0.17) $(0.31)
Diluted $(0.17) $(0.31)
Weighted-average number of shares used in computing earnings per share amounts:        
Basic  16,387,290   14,755,893 
Diluted  16,387,290   14,755,893 
These financial statements should be read in connection with the accompanying notes on Form 10-K for fiscal 2016 filed with the SEC on July 14, 2016. 

About IGC

In the United States, we develop phytocannabinoid-based therapies. We have several patent filings for the indications of Pain, Medical Refractory Epilepsy and Cachexia using phytocannabinoids. In addition, we engage in leasing, trading, developing and managing infrastructure, and real estate projects. We are based in Bethesda, Maryland.

Our website: www.igcinc.us. Twitter @IGCIR Facebook.com/IGCIR/

Forward-looking Statements

Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "intends," "potential," "proposed" or the negative of those terms. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond IGC's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in IGC's business and acquisition and diversification strategy, competitive environment, infrastructure demands, and governmental, regulatory, political, economic, legal and social conditions in, among other places, China and India. Except as required by federal securities laws, IGC undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information or future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.


Contact Data